February 9, 2022

Labcorp enters comprehensive, long-term laboratory relationship with Ascension

BURLINGTON, N.C. --(BUSINESS WIRE)--Feb. 9, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into agreements to create a comprehensive strategic relationship with Ascension, one of the nation’s leading Catholic and non-profit health systems. Through the expansive strategic collaboration, Labcorp will manage Ascension’s hospital-based laboratories in 10 states and purchase select assets of the health system’s outreach laboratory business. This long-term relationship will expand Labcorp’s clinical laboratory services in several states across the country while creating opportunities to enhance care across all clinical areas.
<span>Labcorp strengthens oncology leadership position with the addition of Personal Genome Diagnostics, a provider of comprehensive liquid biopsy and tissue-based genomic products and services</span>
December 23, 2021

Labcorp strengthens oncology leadership position with the addition of Personal Genome Diagnostics, a provider of comprehensive liquid biopsy and tissue-based genomic products and services

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 23, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.
<span>Labcorp and ConcertAI optimize precision oncology research with real-world data and artificial intelligence</span>
December 1, 2021

Labcorp and ConcertAI optimize precision oncology research with real-world data and artificial intelligence

BURLINGTON, N.C. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 1, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, and ConcertAI, LLC (ConcertAI), a leader in enterprise artificial intelligence (AI) and real-world data (RWD) solutions for life science companies and health care providers, today announced a collaboration to optimize precision oncology research. The companies will work together to launch clinical studies in ways that minimize the burden on physician practices, drive faster patient recruitment, maximize patient retention and ensure equitable access to research as a care option.
<span>Labcorp and National Kidney Foundation promote patient registry to enhance clinical trial accessibility, diversity</span>
November 4, 2021

Labcorp and National Kidney Foundation promote patient registry to enhance clinical trial accessibility, diversity

BURLINGTON, N.C. & NEW YORK --(BUSINESS WIRE)--Nov. 4, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, and the National Kidney Foundation (NKF), the largest patient organization dedicated to the prevention and treatment of kidney disease, announced their collaboration to promote the NKF Patient Network, the first national registry for chronic kidney disease (CKD) patients in the U.S. The NKF Patient Network will offer greater data and insights to physicians, as well as improved clinical trial access for patients with kidney disease.